| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000016860 |
| Receipt No. | R000019571 |
| Official scientific title of the study | Comparison examination of microbiota in mouth, intestine and vagina before and after medication of a raw bacillus agent (an active bacterial probiotics, Bio-Three) to the threatened premature delivery patient who requires in-hospital treatment, and examination about validity of preterm delivery medical treatment |
| Date of disclosure of the study information | 2015/03/21 |
| Last modified on | 2017/12/11 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Comparison examination of microbiota in mouth, intestine and vagina before and after medication of a raw bacillus agent (an active bacterial probiotics, Bio-Three) to the threatened premature delivery patient who requires in-hospital treatment, and examination about validity of preterm delivery medical treatment | |
| Title of the study (Brief title) | Comparison examination of microbiota in mouth, intestine and vagina before and after medication of a raw bacillus agent to threatened preterm delivery, and examination about validity of preterm delivery medical treatment | |
| Region |
|
|
| Condition | ||
| Condition | threatened preterm delivery | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To perform a raw bacillus agent (Bio-Three®, 6 tablets per day) medication to patients of threatened preterm delivery who need in-hospital treatment and
To evaluate a change of microbiota in mouth, intestine and vagina before and after medication by the T-RFLP (Terminal restriction fragment length polymorphism) method and meta-genomics analysis using a next-generation sequencer |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | a change of microbiota in mouth, intestine and vagina |
| Key secondary outcomes | |
| Base | |
| Study type | |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | A raw bacillus agent (Bio-Three 6 tablets per day, 14 days) is prescribed. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | a patient of threatened preterm delivery (tocolysis index, 2 to 6) who needs in-hospital treatment, who was transferred from other hospitals or was out-patient in our hospital at 22 to 34 weeks of gestation | |||
| Key exclusion criteria | 1) multiple pregnancy
2) previous medication of antibiotics within 14 days 3) premature rupture of the membranes 4) tocolysis index of 7 or higher (there is a possibility of becoming a preterm delivery within one week) 5) allergy to Bio-Three 6) ulcerative colitis and Crohn's disease |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Shigeru Saito |
| Organization | University of Toyama |
| Division name | OB/GYN |
| Address | 2630 Sugitani Toyama |
| TEL | 076-434-7355 |
| s30saito@med.u-toyama.ac.jp | |
| Public contact | |
| Name of contact person | Arihiro Shiozaki |
| Organization | University of Toyama |
| Division name | Obstetrics and Gynecology |
| Address | 2630 Sugitani, Toyama |
| TEL | 076-434-7357 |
| Homepage URL | |
| s33shio@med.u-toyama.ac.jp | |
| Sponsor | |
| Institute | University of Toyama |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Toa Pharmaceutical Co., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019571 |